MP-424 — Competitive Intelligence Brief

MP-424 (MP-424) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HCV NS3/4A protease inhibitor. Area: Virology/Hepatology.

phase 3 HCV NS3/4A protease inhibitor HCV NS3/4A protease Virology/Hepatology Small molecule

Target snapshot

MP-424 (MP-424) — Tanabe Pharma Corporation. MP-424 is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication by preventing the cleavage of viral polyproteins.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MP-424 TARGET	MP-424	Tanabe Pharma Corporation	phase 3	HCV NS3/4A protease inhibitor	HCV NS3/4A protease
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]	Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
Glecaprevir and Pibrentasvir	Glecaprevir and Pibrentasvir	Massachusetts General Hospital	marketed	Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor)	HCV NS3/4A protease and NS5A protein
paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin	paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin	American Research Corporation	marketed	HCV protease inhibitor / NS5A inhibitor / polymerase inhibitor combination	HCV NS3/4A protease, NS5A protein, NS5B polymerase
Grazaoprevir/Elbasavir	Grazaoprevir/Elbasavir	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
ABT450r-ABT267-ABT333 +/- Ribavirin	ABT450r-ABT267-ABT333 +/- Ribavirin	Ottawa Hospital Research Institute	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease, NS5A protein, NS5B polymerase
Sofosbuvir/Velpatasvir/Voxilaprevir	Sofosbuvir/Velpatasvir/Voxilaprevir	Peking University People's Hospital	marketed	Direct-acting antiviral (DAA) combination; NS5B polymerase inhibitor + NS5A inhibitor + NS3/4A protease inhibitor	HCV NS5B polymerase, HCV NS5A protein, HCV NS3/4A protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HCV NS3/4A protease inhibitor class)

1. Bristol-Myers Squibb · 1 drug in this class
2. Tanabe Pharma Corporation · 1 drug in this class